[go: up one dir, main page]

WO2007012838A3 - Drug delivery system - Google Patents

Drug delivery system Download PDF

Info

Publication number
WO2007012838A3
WO2007012838A3 PCT/GB2006/002772 GB2006002772W WO2007012838A3 WO 2007012838 A3 WO2007012838 A3 WO 2007012838A3 GB 2006002772 W GB2006002772 W GB 2006002772W WO 2007012838 A3 WO2007012838 A3 WO 2007012838A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
drug
delivery system
drug delivery
drug carrier
Prior art date
Application number
PCT/GB2006/002772
Other languages
French (fr)
Other versions
WO2007012838A2 (en
Inventor
Patrick Bailey
Original Assignee
Univ Manchester
Patrick Bailey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester, Patrick Bailey filed Critical Univ Manchester
Publication of WO2007012838A2 publication Critical patent/WO2007012838A2/en
Publication of WO2007012838A3 publication Critical patent/WO2007012838A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to peptides and peptide analogues/derivatives, for use as peptide drug carrier molecules, and peptide drug carrier-drug conjugates which are transported across the wall of the gut into the blood by PepTl protein. There is provided a drug carrier comprising a peptide, or derivative or analogue thereof, the peptide comprising at least two amino acid residues linked by a peptide bond. The amino acid residues are arranged such that the peptide bond is protected from hydrolysis. The peptide comprises a functional group for attachment to a drug. The functional group to which the drug is attached is provided on the second or C-terminal residue of the peptide.
PCT/GB2006/002772 2005-07-27 2006-07-25 Drug delivery system WO2007012838A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0515363.0 2005-07-27
GBGB0515363.0A GB0515363D0 (en) 2005-07-27 2005-07-27 Drug delivery system

Publications (2)

Publication Number Publication Date
WO2007012838A2 WO2007012838A2 (en) 2007-02-01
WO2007012838A3 true WO2007012838A3 (en) 2007-05-03

Family

ID=34976643

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/002772 WO2007012838A2 (en) 2005-07-27 2006-07-25 Drug delivery system

Country Status (2)

Country Link
GB (1) GB0515363D0 (en)
WO (1) WO2007012838A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156648A1 (en) * 2016-03-18 2017-09-21 广州诺威生物技术有限公司 Compound having anti-inflammatory effect
CN106279353A (en) * 2016-03-18 2017-01-04 广州诺威生物技术有限公司 A kind of compound for antiinflammatory

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099338A2 (en) * 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099338A2 (en) * 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRODIN BIRGER; NIELSEN CARSTEN UHD; STEFFANSEN BENTE; FROKJAER SVEN: "Transport of peptidomimetic drugs by the intestinal Di/tri-peptide transporter, PepT1", PHARMACOLOGY & TOXICOLOGY, vol. 90, no. 6, June 2002 (2002-06-01), pages 285 - 296, XP002403283 *
LEPIST E I; KUSK T; LARSEN D H; ANDERSEN D; FROKJAER S; TAUB M E; VESKI P; LENNERNÄS H; FRIEDRICHSEN G; STEFFANSEN B: "Stability and in vitro metabolism of dipeptide model prodrugs with affinity for the oligopeptide transporter", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 11, no. 1, July 2000 (2000-07-01), pages 43 - 50, XP002403282 *
TAUB M E; DUE LARSEN B; STEFFANSEN B; FROKJAER S: "[beta]-Carboxylic acid esterified D-Asp-Ala retains a high affinity for the oligopeptide transporter in Caco-2 monolayers", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 146, no. 2, 15 January 1997 (1997-01-15), pages 205 - 212, XP002403281 *
THOMSEN AE; FRIEDRICHSEN GM; SORENSEN AH; ANDERSEN R; NIELSEN CU; BRODIN B; EGTRUP M; FROKJAER S; STEFFANSEN B: "Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1: affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism", JOURNAL OF CONTROLLED RELEASE, vol. 86, no. 2-3, 17 January 2003 (2003-01-17), pages 279 - 292, XP004401122 *

Also Published As

Publication number Publication date
GB0515363D0 (en) 2005-08-31
WO2007012838A2 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
WO2006031811A3 (en) Glycopegylated interferon alpha
JP5209463B2 (en) Acylated GLP-1 compounds
JP5755398B2 (en) Elongated GLP-1 compound
EP2717898B1 (en) Pro-coagulant compounds and methods of use thereof
CA2651990C (en) Improved antimicrobial peptides
JP7250814B2 (en) Novel GLP-1 analogues
WO2005056760A3 (en) Glycopegylated follicle stimulating hormone
WO2007022512A3 (en) Glycopegylated factor vii and factor viia
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
MX2010002460A (en) Complexes of rna and cationic peptides for transfection and for immunostimulation.
UA103154C2 (en) Hla-a*-1101-restricted wt1 peptide and pharmaceutical composition comprising thereof
WO2005055950A3 (en) Glycopegylated factor ix
WO2006074467A3 (en) Glycopegylated granulocyte colony stimulating factor
JP2002530430A (en) Pharmaceutical composition for inhibiting hepatitis C virus NS3 protease
WO2007096662A3 (en) Cancer imaging and treatment
MX2009002999A (en) Protease resistant insulin analogues.
WO2004089280A3 (en) Reversible pegylated drugs
WO2006119388A8 (en) Methods for the production of peptide having a c-terminal amide
WO2008098749A3 (en) Peptides derived from the major allergen of ragweed (ambrosia artemisiifolia) and uses thereof
MX2009013635A (en) Influenza inhibiting compositions and methods.
JP2011518179A5 (en)
WO2007144198B1 (en) Fplr-1 inhibitors for use in diseases involving amyloid-induced inflammatory events (flipr and flipr-like) and immunecomplex-mediated diseases
JP2012506408A5 (en)
Shi et al. Strategies to optimize peptide stability and prolong half-life
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06765097

Country of ref document: EP

Kind code of ref document: A2